Long‐term results of the combination of the N7 induction chemotherapy and the busulfan‐melphalan high dose chemotherapy

To evaluate long‐term survival of the first cohort of stage‐4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of the primary tumor and high‐dose chemotherapy (HDC) containing Busulfan–Melphalan (Bu‐Mel) followed by autologous stem cell transplantation (ASCT).

[1]  M. Garami,et al.  Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[3]  K. Matthay,et al.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Valteau‐Couanet,et al.  Event-free survival of patients with high-risk neuroblastoma treated with an N6-like induction treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Berthold,et al.  Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. , 2005, The Lancet. Oncology.

[6]  S. Cotterill,et al.  High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG‐1) by the European Neuroblastoma Study Group , 2005, Pediatric blood & cancer.

[7]  C. Bergeron,et al.  Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Cheung,et al.  Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Frappaz,et al.  LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[11]  G. Vassal,et al.  Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution , 1999, Bone Marrow Transplantation.

[12]  N. Callander,et al.  Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation , 1998, Annals of Internal Medicine.

[13]  D. Frappaz,et al.  Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Leverger,et al.  NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Gerald,et al.  Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[17]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[19]  C. R. Pinkerton,et al.  Cisplatin ototoxicity in children: a practical grading system. , 1991, Medical and pediatric oncology.

[20]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .